John Newman Analyst PerformanceAnalyst at Canaccord Genuity GroupJohn Newman is a stock analyst at Canaccord Genuity Group focused in the medical sector, covering 45 publicly traded companies. Over the past year, John Newman has issued 7 stock ratings, including and buy recommendations. While full access to John Newman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights John Newman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings390 Last 11 YearsBuy Recommendations90.75% 353 Buy RatingsCompanies Covered45 Unique Companies Ratings Distribution389RatingsDistribution of strong buy, buy, hold, and sell ratings by John Newman.RatingPercentageCount Strong Buy0.0%0 ratings Buy90.7%353 ratings Hold9.3%36 ratings Sell0.0%0 ratingsOut of 389 total stock ratings issued by John Newman at Canaccord Genuity Group, the majority (90.7%) have been Buy recommendations, followed by 9.3% Hold.Best & Worst CallsBest Call0000.0%DMTXJun 2017Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%VSARSep 2017Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ88.9% of companies on NASDAQ40 companiesNYSE8.9% of companies on NYSE4 companiesPINK2.2% of companies on PINK1 companyJohn Newman, an analyst at Canaccord Genuity Group, currently covers 45 companies listed on NASDAQ, NYSE and PINK, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical39 companies86.7%Miscellaneous4 companies8.9%Finance1 company2.2%Business Services1 company2.2%John Newman of Canaccord Genuity Group specializes in stock coverage within the Medical sector, with additional focus on and Finance companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE15 companies33.3%PHARMACEUTICAL PREPARATIONS13 companies28.9%MED - DRUGS4 companies8.9%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC4 companies8.9%Miscellaneous4 companies8.9%BIOTECHNOLOGY2 companies4.4%FIRE, MARINE, & CASUALTY INSURANCE1 company2.2%GOVERNMENT SERVICES1 company2.2%MED - GENERIC DRG1 company2.2% John Newman's Ratings History at Canaccord Genuity Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export to Excel CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsREGNRegeneron Pharmaceuticals7/23/2025Reiterated Rating$572.92$850.00Buy$0.0000.00% ROIALLOAllogene Therapeutics3/14/2025Reiterated Rating$1.90$14.00Buy$0.0000.00% ROIATRAAtara Biotherapeutics3/11/2025Reiterated Rating$6.16$17.00Buy$0.0000.00% ROIBNTXBioNTech3/11/2025Reiterated Rating$103.54$171.44Buy$0.0000.00% ROIMRKRMarker Therapeutics3/5/2025Initiated Coverage$1.38$8.00Buy$0.0000.00% ROICADLCandel Therapeutics2/19/2025Initiated Coverage$9.52$20.00Buy$0.0000.00% ROIATRAAtara Biotherapeutics1/17/2025Lower Price Target$6.88$17.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
